Article: Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)
File Download
(May Require Subscription)
- No File Attached
(May Require Subscription)
- Publisher Website: 10.1021/pr901085z
- Scopus: eid_2-s2.0-77950647292
- PMID: 20121168
- Find via
Supplementary
-
Citations:
-
Appears in Collections:
| Title | Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm) | ||||||
|---|---|---|---|---|---|---|---|
| Authors | Sun, S2 Poon, RTP2 Lee, NP2 Yeung, C2 Chan, KL2 Ng, IOL2 Day, PJR1 Luk, JM2 3 | ||||||
| Keywords | AFP Biomarker Cancer screening HCC Tumor detection Tumor size | ||||||
| Issue Date | 2010 | ||||||
| Publisher | American Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobs | ||||||
| Citation | Journal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930 [How to Cite?] DOI: http://dx.doi.org/10.1021/pr901085z | ||||||
| Abstract | Small hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (≤2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (≤2 cm) with p < 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p < 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. © 2010 American Chemical Society. | ||||||
| ISSN | 1535-3893 2011 Impact Factor: 5.113 2011 SCImago Journal Rankings: 0.642 | ||||||
| DOI | http://dx.doi.org/10.1021/pr901085z | ||||||
| ISI Accession Number ID | WOS:000276215700028
Funding Information: The work was supported by grants from the Research Grants Council of Hong Kong (771607M) and National Medical Research Council to J.M.L. We also thank for the generous donation from the Sun Chien Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery. We sincerely acknowledge Dr. W. C. Yu for giving clinical assistance in specimen collection and preparation. We also thank Dr. Wilson Y.P. Ching in Department of Anatomy, The University of Hong Kong for providing the monoclonal vimentin antibody in our preliminary studies. Irene Ng is Loke Yew Professor of Pathology. | ||||||
| References | References in Scopus |
| dc.contributor.author | Sun, S | ||||||
|---|---|---|---|---|---|---|---|
| dc.contributor.author | Poon, RTP | ||||||
| dc.contributor.author | Lee, NP | ||||||
| dc.contributor.author | Yeung, C | ||||||
| dc.contributor.author | Chan, KL | ||||||
| dc.contributor.author | Ng, IOL | ||||||
| dc.contributor.author | Day, PJR | ||||||
| dc.contributor.author | Luk, JM | ||||||
| dc.date.accessioned | 2010-09-06T09:43:54Z | ||||||
| dc.date.available | 2010-09-06T09:43:54Z | ||||||
| dc.date.issued | 2010 | ||||||
| dc.description.abstract | Small hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (≤2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (≤2 cm) with p < 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p < 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. © 2010 American Chemical Society. | ||||||
| dc.description.nature | Link_to_subscribed_fulltext | ||||||
| dc.identifier.citation | Journal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930 [How to Cite?] DOI: http://dx.doi.org/10.1021/pr901085z | ||||||
| dc.identifier.doi | http://dx.doi.org/10.1021/pr901085z | ||||||
| dc.identifier.epage | 1930 | ||||||
| dc.identifier.hkuros | 169635 | ||||||
| dc.identifier.isi | WOS:000276215700028
Funding Information: The work was supported by grants from the Research Grants Council of Hong Kong (771607M) and National Medical Research Council to J.M.L. We also thank for the generous donation from the Sun Chien Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery. We sincerely acknowledge Dr. W. C. Yu for giving clinical assistance in specimen collection and preparation. We also thank Dr. Wilson Y.P. Ching in Department of Anatomy, The University of Hong Kong for providing the monoclonal vimentin antibody in our preliminary studies. Irene Ng is Loke Yew Professor of Pathology. | ||||||
| dc.identifier.issn | 1535-3893 2011 Impact Factor: 5.113 2011 SCImago Journal Rankings: 0.642 | ||||||
| dc.identifier.issue | 4 | ||||||
| dc.identifier.openurl | | ||||||
| dc.identifier.pmid | 20121168 | ||||||
| dc.identifier.scopus | eid_2-s2.0-77950647292 | ||||||
| dc.identifier.spage | 1923 | ||||||
| dc.identifier.uri | http://hdl.handle.net/10722/88478 | ||||||
| dc.identifier.volume | 9 | ||||||
| dc.language | eng | ||||||
| dc.publisher | American Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobs | ||||||
| dc.publisher.place | United States | ||||||
| dc.relation.ispartof | Journal of Proteome Research | ||||||
| dc.relation.references | References in Scopus | ||||||
| dc.subject.mesh | Carcinoma, Hepatocellular - blood - diagnosis - pathology | ||||||
| dc.subject.mesh | Liver Neoplasms - blood - diagnosis - pathology | ||||||
| dc.subject.mesh | Proteomics - methods | ||||||
| dc.subject.mesh | Tumor Markers, Biological - blood | ||||||
| dc.subject.mesh | Vimentin - blood | ||||||
| dc.subject | AFP | ||||||
| dc.subject | Biomarker | ||||||
| dc.subject | Cancer screening | ||||||
| dc.subject | HCC | ||||||
| dc.subject | Tumor detection | ||||||
| dc.subject | Tumor size | ||||||
| dc.title | Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm) | ||||||
| dc.type | Article |
Author Affiliations
- University of Manchester
- The University of Hong Kong
- National University of Singapore